Abstract
Dengue fever and dengue hemorrhagic fever are transmitted to humans by the Aedes aegypti and Aedes albopictus mosquitoes, with an observed 30-fold increase in global incidence the last 50 years. Despite the tremendous efforts invested anti-dengue virus research, no clinically approved vaccine or antiviral chemotherapeutics are available for humans, and disease treatment is limited to supportive care. Over the years there has been a continuous interest in the chemistry of metal complexes with biological activity, including platinum complexes with antitumor activity and silver complexes with antimicrobial action. Aim of the project was to investigate [Cu(2,4,5-triphenyl-1Himidazole) (2) (H(2)O)(2)].Cl(2) as antiviral compound that was further tested for inhibitory effect on the replication of dengue virus type 2 (DENV-2) in Vero cell. DENV-2 were infected in Vero cells and replication of virus was measured by Viral ToxGlo with selectivity index value (SI) and determined as the ratio of cytotoxic concentration 50 (CC(50)) to inhibitory concentration 50 (IC(50)) for compound. The standard curve between concentration of compound (μg/mL) and %viability of cells was analyzed by logarithmic correlation regression with regression equation. For infection rates, t-test was used to examine the statistical significances among the concentrations of compound. P<0.05 was considered to be significant. The maximum inhibitory concentration (IC(50)) of [Cu(2,4,5- triphenyl-1H-imidazole)(2) (H(2)O)(2)].Cl(2) against DENV-2 was 98.62 μg/mL. The cytotoxic concentration (CC(50)) of compound against Vero cells was 300.36μg/mL. The SI values for [Cu(2,4,5-triphenyl-1H-imidazole)(2) (H(2)O)(2)].Cl(2) 1.86.Based on selectivity index values, [Cu(2,4,5-triphenyl-1H-imidazole)(2) (H(2)O)(2)].Cl(2) can inhibit the growth of DENV- 2 and has low toxicity values for Vero cells.